Third-generation skin growth factor receptor inhibitor drug-resistant mutation neoantigen and application thereof

• Main Authors: ZHANG XIAOXIA, ZHAO YONGHAO, J. PENG, MA SAI, YAN CHENGHAI, ZHANG CHONGQIAN, D. ZHANG
• Format: Patent
• Language: Chinese; English
• Published: 24.08.2021
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The invention provides a neoantigen (amino acid sequences such as SEQ ID No1: QLMPFGSLL and SEQ ID No02: QLMPFSCLL) of an epidermal growth factor receptor fragment sequence representing drug resistance point mutation of a third-generation skin growth factor receptor inhibitor drug-resistant mutation neoantigen, EGFR inhibitor and a pharmaceutical composition containing the peptide or RNA and used for treating non-small cell lung cancer, and the series of antigen peptides have the effect of activating T cells, and can be used for treating non-small cell lung cancer. A novel immunotherapy method is provided for preventing drug resistance of the third-generation EGFR inhibitor and treating non-small cell lung cancer with EGFR mutation or EGFR-TKI drug resistance in combination with the third-generation EGFR inhibitor. 本申请发明提供了第三代表皮生长因子受体(EGFR)抑制剂耐药点突变的表皮生长因子受体片段序列的新生抗原(氨基酸序列如SEQ ID No1：QLMPFGSLL和SEQ ID No 02：QLMPFSCLL)，以及包含该肽或RNA的用于治疗非小细胞肺癌的药物组合物，该系列抗原肽具有激活T细胞的作用，为预防第三代EGFR抑制剂耐药、联合三代EGFR抑制剂治疗EGFR突变或者EGFR-TKI耐药的非